Back to BlackRock, Inc. BlackRock, Inc.

LCTXLCTX
8 quarters

Position history for BlackRock, Inc.BlackRock, Inc.'s holdings in LINEAGE CELL THERAPEUTICS IN

Yes. BlackRock holds 13,186,895 shares of LCTX (Lineage Cell Therapeutics in), worth $17.3M, as of its Q2 2026 13F filing. It increased the position from 3,864,757 shares in Q1 2026. BlackRock has held LCTX in every 13F on record since Q3 2024, 8 quarterly filings.

Current Value

$17.3M

Current Shares

13.2M

Total Value Change

+$8.3M

Total Shares Change

+3.3M

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Increased
13.2M
+241.2%
$17.3M0.0%$1.31
46
2026-Q1
Increased
3.9M
+0.8%
$6.1M0.0%$1.58
27
2025-Q4
Increased
3.8M
+71.9%
$6.4M0.0%$1.67
41
2025-Q3
Decreased
2.2M
-1.3%
$3.8M0.0%$1.69
0
2025-Q2
Decreased
2.3M
-80.3%
$2.1M0.0%$0.91
0
2025-Q1
Increased
11.5M
+13.5%
$5.2M0.0%$0.45
31
2024-Q4
Increased
10.1M
+1.8%
$5.1M0.0%$0.50
27
2024-Q3
First report
9.9M
-
$9M0.0%$0.91
0

Other major holders of LCTX: VANGUARD GROUP INC, STATE STREET CORP, VANGUARD CAPITAL MANAGEMENT LLC, BlackRock Finance, Inc.

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used